San Francisco Bay area adult glioma survival study

描述（由申请人提供）：确定相关的肿瘤和患者特征可能有助于为每个胶质瘤患者选择最佳治疗方法，增强基于统一预后的临床试验均匀亚组的定义，以便快速评估治疗，并为患者提供更好的预后信息。为了确定相关特征，本研究将检查生存率与几种具有潜在预后价值的肿瘤标志物的关系，已知的预后患者特征（如年龄），以及那些尚未研究的与胶质瘤预后相关的因素，包括DNA修复和致癌物质代谢基因的各种多态性，个人和家庭病史，诊断前的饮食，吸烟和饮酒，以及其他人口统计学因素。该研究的具体目的是：(1)确定到2004年的生命状态以及1991-94年和1997-99年之间诊断的881例成人发病胶质瘤病例的相关治疗信息，这些病例是旧金山湾区成人胶质瘤的一部分

DESCRIPTION (provided by applicant): The identification of relevant tumor and patient characteristics is likely to aid in choosing the best treatments for each glioma patient, in enhancing definition of homogeneous subgroups for clinical trials based on uniform prognosis for rapid treatment evaluation, and in providing better prognostic information to patients. To identify relevant characteristics, this study will examine survival in relationship to several tumor markers with potential prognostic value, patient characteristics known to be prognostic (such as age), and those factors as yet unstudied in relation to glioma prognosis including a variety of polymorphisms in DNA repair and carcinogen metabolizing genes, personal and family medical histories, diet, smoking and alcohol consumption prior to diagnosis, and other demographic factors. The study's specific aims are to: (1) Determine vital status through 2004 and relevant treatment information or 881 population based adult onset glioma cases diagnosed between 1991-94 and 1997-99 and interviewed as part of the San Francisco Bay Area Adult Glioma Study (an ongoing NCI funded study of the genetic and molecular epidemiology of adult glioma). (2) Use Cox regressions and recursive partitioning analysis to determine survival as a function of both established, potential, and as yet unstudied prognostic indicators; (3) Validate results obtained from aim 2 in newly diagnosed GM patients on clinical trial protocols at UCSF. We will collect blood, buccal and tumor specimens and clinical and brief questionnaire data for newly diagnosed patients seen at the UCSF Neuro-Oncology Service from July 1, 2002-June 30, 2006. Promising markers identified in aim 2 will be assayed for 100 of these GM cases on clinical trial protocols and incorporated into a validation survival analysis. This study provides a unique opportunity to examine survival in a large, population-based group of patients with epidemiologic risk factor data, constitutive DNA specimens, and tumor marker data and thus to preliminarily evaluate markers that will then be incorporated into prospective clinical trials for validation.